10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody
Catalog # AP63171

Specification

Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody - Product Information

Application	**WB**
Primary Accession	P01042
Reactivity	**Human**
Host	**Rabbit**
Clonality	**Polyclonal**

Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody - Additional Information

Gene ID 3827

Other Names
KNG1; BDK; KNG; Kininogen-1; Alpha-2-thiol proteinase inhibitor; Fitzgerald factor; High molecular weight kininogen; HMWK; Williams-Fitzgerald-Flaujeac factor

Dilution
WB~~Western Blot: 1/500 - 1/2000. ELISA: 1/10000. Not yet tested in other applications.

Format
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.09% (W/V) sodium azide.

Storage Conditions
-20℃

Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody - Protein Information

Name KNG1

Synonyms BDK, KNG

Function
Kininogens are inhibitors of thiol proteases. HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; HMW-kininogen inhibits the thrombin- and plasmin-induced aggregation of thrombocytes. LMW-kininogen inhibits the aggregation of thrombocytes. LMW-kininogen is in contrast to HMW-kininogen not involved in blood clotting.

Cellular Location
Secreted, extracellular space.

Tissue Location
Secreted in plasma. T-kinin is detected in malignant ovarian, colon and breast carcinomas, but not in benign tumors.

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation
- Flow Cytomety
- Cell Culture

Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody - Images



Cleaved-Kininogen-1 HC (K380) Polyclonal Antibody - Background

(1) Kininogens are inhibitors of thiol proteases; (2) HMW-kininogen plays an important role in blood coagulation by helping to position optimally prekallikrein and factor XI next to factor XII; (3) HMW-kininogen inhibits the thrombin- and plasmin- induced aggregation of thrombocytes; (4) the active peptide bradykinin that is released from HMW-kininogen shows a variety of physiological effects: (4A) influence in smooth muscle contraction, (4B) induction of hypotension, (4C) natriuresis and diuresis, (4D) decrease in blood glucose level, (4E) it is a mediator of inflammation and causes (4E1) increase in vascular permeability, (4E2) stimulation of nociceptors (4E3) release of other mediators of inflammation (e.g. prostaglandins), (4F) it has a cardioprotective effect (directly via bradykinin action, indirectly via endothelium-derived relaxing factor action); (5) LMW-kininogen inhibits the aggregation of thrombocytes; (6) LMW- kininogen is in contrast to HMW-kininogen not involved in blood clotting.